News

ondelis is approved for patients with two forms of STS, liposarcoma or leiomyosarcoma, who had earlier received chemotherapy that contained anthracycline. While it is approved for both leiomyosarcoma

The company received a complete response letter, which the FDA sends to a company to inform that the marketing application will not be approved in its existing form.

Imlygic, also known as talimogene laherparepvec (T-Vec), is recommended to treat adults with unresectable melanoma that is regionally or distantly metastatic with no bone, brain, lung or other

In total, the actions are expected to add incremental benefits of $175m when the full run rate of the plan is achieved. With the inclusion of approximately $0.153

Professor David E. Thurston of the Institute of Pharmaceutical Science will lead a team at King’s to develop and optimize a range of specific small molecules for Auris

Strensiq, an innovative enzyme replacement therapy (ERT), is the first therapy approved in the U.S. for the treatment of patients with HPP, a genetic, chronic, and progressive ultra-rare

The expansion of the plant became necessary to make room for research and development, quality management, laboratory, production and logistics. 2,250 square meters of clean room space, certified

In March 2015, RedHill Biopharma acquired from Apogee the exclusive worldwide rights to YELIVA (ABC294640), a first-in-class, orally-administered sphingosine kinase-2 ("SK2") selective inhibitor. Following prior pre-clinical studies in

GDC-0310 is a selective, oral Nav1.7 small-molecule inhibitor, identified as part of the companies’ pain collaboration focused on the Nav1.7 target. Genentech has initiated a Phase 1 clinical